What Is Dihexa?
Dihexa (N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide) was developed at Washington State University by Joseph W. Harding and colleagues. It's a small, orally bioavailable peptidomimetic — meaning it mimics the function of a larger peptide but in a compact, stable form that can be taken systemically.
Its core mechanism centers on potentiation of the HGF/c-Met signaling axis, a pathway critical to neuronal survival, synaptic formation, and long-term potentiation (LTP). Early preclinical studies showed Dihexa to be approximately 10 million times more potent than brain-derived neurotrophic factor (BDNF) at promoting synaptogenesis in rodent models — a staggering benchmark that placed it at the frontier of cognitive neuroscience research.
Dihexa is currently investigational. It is not FDA-approved for any medical indication and all data referenced here derives from preclinical and early-stage research.
How Dihexa Works: Rebuilding Synaptic Architecture
Dihexa's therapeutic potential hinges on its ability to amplify hepatocyte growth factor (HGF) and its receptor c-Met — a signaling duo that governs some of the brain's most fundamental repair processes.
HGF/c-Met Potentiation
Dihexa binds HGF and enhances its binding affinity to c-Met receptors on neurons, dramatically amplifying downstream repair signaling without directly activating c-Met itself.
Synaptogenesis Activation
Downstream c-Met signaling triggers dendritic spine formation and axonal sprouting — physically rebuilding the synaptic connections lost to injury, disease, or aging.
Long-Term Potentiation
Enhanced synaptic density supports LTP — the cellular basis of memory consolidation — restoring cognitive function in models of neurodegeneration.
Neuronal Survival
c-Met activation promotes anti-apoptotic pathways, protecting existing neurons from programmed cell death during neuroinflammatory or ischemic insults.
Healthy Brain vs. Degenerating Brain
The contrast between a healthy neural environment and one afflicted by neurodegeneration is stark — and it's precisely this gap that Dihexa aims to close by restoring synaptic connectivity at the cellular level.
Healthy Brain
• Dense, richly interconnected dendritic spines
• Robust LTP and efficient neurotransmission
• Active HGF/c-Met signaling sustaining plasticity
• Neurons firing in synchronized, organized networks
Degenerating Brain
• Sparse, fragmented dendritic spines
• Impaired LTP and neurotransmitter dysregulation
• Reduced HGF/c-Met activity and neurotrophic support
• Progressive neuronal apoptosis and circuit collapse
Research Indications Under Investigation
Alzheimer's Disease
In rodent models of Alzheimer's, Dihexa reversed cognitive deficits and restored spatial memory. A patient with early-stage Alzheimer's enrolled in a compassionate-use protocol reportedly experienced measurable improvements in word recall and daily task orientation within weeks of transdermal administration.
Stroke & Ischemic Injury
Post-ischemic neurons face rapid apoptosis. Dihexa's c-Met activation promotes survival of penumbral tissue — the vulnerable zone surrounding a stroke core. Caregivers of post-stroke patients on experimental protocols have described accelerated rehabilitation milestones in speech and motor coordination.
Parkinson's Disease
While primarily a dopaminergic disease, Parkinson's involves widespread synaptic loss. Dihexa may slow this secondary neurodegeneration. Early anecdotal reports note improvements in non-motor symptoms — mental clarity, mood, reduced cognitive fog — alongside standard therapy.
PTSD & Cognitive Decline
Trauma rewires synaptic architecture in the prefrontal cortex and hippocampus. Dihexa's ability to promote new synapse formation may facilitate therapeutic reconsolidation. A veteran participant in an early trial reported improved emotional regulation and reduction in intrusive memory frequency after 8 weeks of low-dose therapy.
TBI & Contact Sports: A Growing Crisis
Traumatic brain injury (TBI) affects an estimated 1.7 million Americans annually, with contact-sport athletes — particularly football players — representing one of the most studied and at-risk populations. Repeated subconcussive impacts accelerate synaptic loss, neuroinflammation, and in chronic cases, the development of Chronic Traumatic Encephalopathy (CTE).
Dihexa's mechanism is directly relevant: by amplifying HGF-mediated repair signaling after acute mechanical injury, it may reduce the cascade of secondary neuronal death that accounts for a majority of long-term TBI disability. Preclinical rodent TBI models showed marked improvement in spatial navigation and reduced cortical lesion volume following Dihexa administration.
- 1.7M: Estimated U.S. annual TBI incidence
- 300K: Sport-related concussions in U.S. athletes per year
- 10M+: Times more potent than BDNF in synaptogenesis models
Dosing & Delivery Methods
Because Dihexa is investigational and not FDA-approved, dosing information is derived exclusively from preclinical studies, researcher communications, and anecdotal self-experimentation reports within the longevity research community. All usage is off-label and should only be pursued under qualified medical supervision.
Transdermal (Most Common)
Dissolved in DMSO or a transdermal cream. Typical reported range: 10–30 mg applied to inner wrist or forearm. Preferred for ease of use and relatively consistent absorption. Onset reported within 30–60 minutes. Frequency: 1–3× per week to avoid tachyphylaxis.
Oral (Capsule)
Orally bioavailable due to peptidomimetic structure. Reported doses: 10–25 mg in capsule form. Bioavailability may be lower than transdermal due to first-pass metabolism. Some protocols suggest sublingual administration for faster uptake.
Subcutaneous Injection
Used in research protocols at lower doses (1–10 mg) for more precise systemic delivery. Injection site: abdomen or upper arm. Not commonly used outside clinical research due to preparation requirements and sterility demands.
Intranasal
An emerging route leveraging direct olfactory-to-CNS transport. Bypasses blood-brain barrier entirely. Early reports suggest doses as low as 1–5 mg intranasally may be effective. Preparation requires pharmaceutical-grade saline suspension.
Cycling protocols (e.g., 2 weeks on / 2 weeks off) are commonly recommended in the research community to maintain receptor sensitivity and avoid downregulation of c-Met signaling over time.
Frequently Asked Questions
What is Dihexa?
Dihexa is a small synthetic peptide developed to potentiate hepatocyte growth factor (HGF) signaling through its receptor, c-Met. This pathway drives synaptogenesis — the formation of new connections between neurons. Dihexa has been reported in preclinical research to be dramatically more potent than BDNF at promoting synapse formation, though this comparison comes from animal and in-vitro work rather than human trials.
How does Dihexa work in the brain?
Dihexa binds to and stabilizes the interaction between hepatocyte growth factor and the c-Met receptor, amplifying a signaling cascade that promotes the growth of new dendritic spines and synaptic connections. Rather than acting as a stimulant that alters neurotransmitter levels, it is intended to change the physical architecture of neural circuits over time.
Is Dihexa well-studied in humans?
No. The great majority of Dihexa evidence comes from rodent models and cell culture. There is very little published human clinical data, and its long-term safety profile in people has not been established. This is a meaningfully less-characterized compound than peptides like Thymosin Alpha-1, and that uncertainty should factor into any evaluation.